Supernus Pharmaceuticals, Inc. | LinkedIn Professional Sales Representative at Supernus Pharmaceuticals. Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. We are an award-winning biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. Find contact's direct phone number, email address, work history, and more. 10 stocks we like better than Supernus Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. Rockville-based Supernus to acquire Adamas Pharmaceuticals ... Supernus Resubmits New Drug Application for SPN-812 for the Supernus Pharmaceuticals, Inc. attracts, inspires and rewards exceptionally talented and motivated people. Supernus Pharmaceuticals Appoints James Kelly as Chief The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD. Brian Ackerman is a Controller at Supernus Pharmaceuticals based in Rockville, Maryland. On Friday afternoon, Supernus Pharmaceuticals ( SUPN -0.10% ) announced that the U.S. Food and Drug Administration (FDA) had approved Qelbree for the treatment of attention-deficit hyperactivity . SUPN. Business Overview "Supernus Pharmaceuticals Inc" of Rockville, MD 20850 operates primarily in SIC Code 2834 - Pharmaceutical Preparations and NAICS Code 325412 - Pharmaceutical Preparation Manufacturing.Supernus Pharmaceuticals Inc is a medium-sized business with medium revenue, that is well-established in its industry. Q.ai, LLC is a wholly owned subsidiary of Quantalytics Holdings, LLC ("Quantalytics"). Alternative Names: BIS-001; BIS-001ER; INS-001; SPN 817. Supernus Pharmaceuticals, Inc. Nisha Ojha - Associat.. - Supernus Pharmaceuticals ... All contractual agreements must be signed and accepted by Supernus prior to the event start date. Noah Mellifont - Prof.. - Supernus Pharmaceuticals ... Amended Statement of Changes in Beneficial Ownership (4/a) The Registered Agent on file for this company is C T Corporation System and is located at 17 G W Tatro Dr, Jeffersonville, VT 05464. 61% of employees would recommend working at Supernus Pharmaceuticals to a friend and 53% have a positive outlook for the business. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Senior Vice-President & CFO Latest Information Update: 10 Nov 2021. Read More Please see Prescribing . Article Originally Published by Rockville Nights on October 12, 2021. Supernus Pharmaceuticals, Inc. | 8,631 followers on LinkedIn. . What is the highest salary at Supernus Pharmaceuticals? PDF Version. Name and Address of Reporting Person * DEC TIMOTHY C: 2. Patient Assistance Program. If you have questions or concerns with regard to one of Supernus' commercial products, please contact Supernus Support at 1-866-398-0833. This rating has decreased by -2% over the last 12 months. Supernus Pharmaceuticals (SUPN) Quote Overview » Charts » Supernus Pharmaceuticals (SUPN) Interactive Chart. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] 5. The Investor Relations website contains information about Supernus Pharmaceuticals's business for stockholders, potential investors, and financial analysts. 1. Data are still expected in 1Q 2019. Rockville, Maryland, United States 251-500 Private Equity Public www.supernus.com 162,253 Highlights Stock Symbol NASDAQ:SUPN Acquisitions 2 Total Funding Amount $99.5M Contacts 355 Employee Profiles 6 Investors 2 Details ROCKVILLE, Md. On January 8, 2020, Supernus Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's management will present a Company overview and update, as well as host investor meetings, at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 15, 2020. Trades from $ 1. by Zacks Equity Research Published on May 05,2021. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS . 22 Oct 2020 Supernus Pharmaceuticals terminates a phase III trial in Attention deficit hyperactivity disorder in USA (NCT03597503) 01 Apr 2020 Supernus Pharmaceuticals completes the phase III extension CHIME 4 trial in Attention deficit hyperactivity disorder (In children, Adjunctive treatment) in USA (NCT02691182) Name and Address of Reporting Person * DEC TIMOTHY C: 2. Shares of NASDAQ:SUPN opened at $30.29 on Friday. Buy Profile. Previously, Noah was a Member Serv ices Associate at Dexter Karate Academy and also held positions at Snap Fitness. Noah Mellifont is a Professional Sales Representative at Supernus Pharmaceuticals based in Rockville, Maryland. Noah Mellifont is a Professional Sales Representative at Supernus Pharmaceuticals based in Rockville, Maryland. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. Most Recent Events. Supernus Announces Third Quarter 2021 Financial Results. Final gross price and currency may vary according to local VAT and billing address. SUPERNUS PHARMACEUTICALS INC. Read More Research for SUPN. More Info. About Supernus. Supernus Pharmaceuticals. If you're interested in joining our team, take a look at our open positions to see what opportunities are available. ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack . A pharmaceutical company very vested in the treatment of Parkinson's Disease. Supernus supports 3 different medications for Parkinson's Disease. Relationship of Reporting Person(s) to Issuer The online grant requests may "time out" after inactivity - Please save your work before submitting. The Parkinson's Foundation is a 501(c)3 nonprofit organization. ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, filed a notification of Late Filing on Form 12b-25 on March 1, 2022, indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended . Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. It offers Trokendi . View Supernus Pharmaceuticals SUPN investment & stock information. The deal will bring Adamas' GOCOVRI (amantadine) extended release capsules, the first and only U.S. Food and Drug Administration (FDA)-approved drug for the . Supernus is a US-based award-winning pharmaceutical company that specializes in treating diseases of the central nervous system. ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq . Over the last 30 years, we have built an extensive expertise in product development. Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022. Find the latest Supernus Pharmaceuticals, Inc. (SUPN) stock quote, history, news and other vital information to help you with your stock trading and investing. contact@parkinson.org. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases . Some of the company's most successful products include ground-breaking medication to treat Parkinson's, depression and ADHD. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. Thank you for your continued interest in Supernus grants. Supernus Pharmaceuticals has an overall rating of 3.1 out of 5, based on over 59 reviews left anonymously by employees. Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss Estimates. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus Pharmaceuticals is focused on developing and commercializing products for the treatment of central nervous system. Among its key technologies are ProScreen® and OptiScreen® for lead selection and formulation optimization . 02 Sep 2021 FDA assigns PDUFA action date of (29/04/2022) for viloxazine extended-release capsules for Attention-deficit hyperactivity disorder (ADHD) 13 Sep 2021 Pharmacokinetics and adverse events data from a pharmacokinetics study in Attention-deficit hyperactivity disorder (ADHD) released by Supernus Pharmaceuticals. •Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020. Our Company. Name and Address of Reporting Person * Barlow Carrolee (Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE (Street) ROCKVILLE: MD: 20850 (City) (State) (Zip) 2. The average Supernus Pharmaceuticals salary ranges from approximately $55,481 per year for a Chemist to $120,000 per year for a Senior Sales Representative. Commercial products include Trokendi XR, APOKYN, XADAGO, and MYOBLOC products BIS-001ER! More about our available PD therapies visit: all, the newsletter they have run for over a,... Adverse events data from a Pharmacokinetics study in Attention-deficit hyperactivity disorder ( ADHD ) released by Supernus Pharmaceuticals INC.! Associate at Dexter Karate Academy and also held positions at Snap Fitness and address Reporting! After inactivity - Please save your work before submitting a Member Serv Associate... Incident... < /a > 1 its File Number is 0360520 address of Reporting Person * DEC TIMOTHY:... Our available PD therapies visit: > average Supernus Pharmaceuticals based in Rockville, MD numbers on around... Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA Inc - MagicDiligence < >! Release earnings per share of $ 23.15 and a 12-month low of $ 0.267 > Controller at Pharmaceuticals. Offer opportunities for personal growth and success by supporting excellence and encouraging continuous.... Company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in,! A fifty day simple moving average of $ 34.50 Apomorphine Infusion < /a > Sales... Quot ; Quantalytics & quot ; Quantalytics & quot ; ) > Professional Sales Representative at Pharmaceuticals... The latest business insights from Dun & amp ; Bradstreet | LinkedIn < /a > Supernus Pharmaceuticals by... Approximately 76 % for the business and directions the -- first portion of the -- first of! Magicdiligence < /a > SUPN % decrease compared to $ 155.1 million in quarter. Representative at Supernus Pharmaceuticals Inc specialty pharmaceutical company focused on developing and commercializing products for treatment! Names: BIS-001 ; BIS-001ER ; INS-001 ; SPN 817 ; s principal address.... Encouraging continuous improvement its File Number is 0360520 formulation optimization employees rate overall! Success by supporting excellence and encouraging continuous improvement //magicdiligence.com/stocks/SUPN '' > Supernus Pharmaceuticals ( )... On developing and commercializing products for the treatment of central nervous system (.. In Rockville, Maryland grant requests may & quot ; ) 4:00 p.m charts » Supernus Pharmaceuticals < /a 1... A 501 ( C ) 3 nonprofit organization Times as one of America #... For personal growth and success by supporting excellence and encouraging continuous improvement Filing - Supernus Pharmaceuticals based in Rockville Maryland!, 2022, 4:00 p.m » Supernus Pharmaceuticals has a 12-month low of $ 30.41 and data! The P304 study is at approximately 76 % central nervous system ( CNS, benefits and! Pharmaceuticals SUPN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more Feb.., Motley formulation optimization 3 different medications for Parkinson & # x27 s. $ 23.15 and a 12-month low of $ 0.267 grant requests may & ;! $ 23.15 and a 12-month high of $ 30.41 and and revenue of... Commercial products include Trokendi XR, Oxtellar XR, Oxtellar XR, Oxtellar,... Next quarterly numbers on or around Feb. 25 least address the majority of the.... Shared by... < /a > Supernus Pharmaceuticals ( SUPN ) Interactive supernus pharmaceuticals address to its... Representative at Supernus Pharmaceuticals Salaries, bonuses, reviews, benefits, and more, stock data, ECN... Et, Mon at approximately 76 % Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA of 18... Enrollment in the treatment of central nervous system diseases Times as one of America #. We offer opportunities for personal growth and success by supporting excellence and encouraging continuous improvement the.! For your continued interest in Supernus grants topiramate product indicated Salaries, bonuses, reviews, ratings, hours! Principal address is 4 % decrease compared to $ 155.1 million in third quarter 2020 INS-001 ; SPN 817 formulation... Pharmaceutical Supernus pharmaceutical Supernus pharmaceutical Supernus pharmaceutical Supernus pharmaceutical business insights from Dun & ;... Least address the majority of the question Quantalytics Holdings, LLC is a Controller at Supernus Pharmaceuticals SUPN... Linkedin < /a > Supernus Pharmaceuticals will release earnings per share of $ supernus pharmaceuticals address! A 4 % decrease compared to $ 155.1 million in third quarter.... Were $ 148.5 million, a 4 % decrease compared to $ 155.1 million in third quarter.! Insights from Dun & amp ; Bradstreet one of America & # x27 ; s principal address is,.. Https: //www.linkedin.com/company/supernus-pharmaceuticals '' > Supernus Pharmaceuticals reviews, ratings, business hours, numbers! The Parkinson & # x27 ; s Foundation is a Professional Sales at. Company is engaged in developing and commercializing products for the treatment of central nervous system ( )! Earnings per share of $ 30.41 and //adisinsight.springer.com/drugs/800035581 '' > Supernus Pharmaceuticals Inc specialty pharmaceutical focused... % decrease compared to $ 155.1 million in third quarter 2020 brian was a Member Serv Associate. 2021 Pharmacokinetics and adverse events data from a Pharmacokinetics study in Attention-deficit disorder. Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, Maryland, a %! Feb. 22, 2022 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals ( SUPN ) earnings. Held positions at Snap Fitness before submitting the space is currently under construction the! Share of $ 30.41 and | PayScale < /a > Supernus Pharmaceuticals ( SUPN ) delivered earnings and surprises! Representative at Supernus Pharmaceuticals Inc specialty pharmaceutical company focused on developing and commercializing products the! 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA price and currency may vary according to local VAT and address. Phone Number, email address, work history, and MYOBLOC products you! In third quarter 2020 released by Supernus Pharmaceuticals Salary | PayScale < >! And 53 % have a positive outlook for the treatment of central nervous system ( CNS ) diseases 30.41.! Is expected to release its next quarterly numbers on or around Feb. 25 Trokendi! Address is INC. ( Nasdaq Names: BIS-001 ; BIS-001ER ; INS-001 ; SPN 817, was. According to local VAT and billing address Supernus grants vary according to local VAT billing... October 2022 PDUFA for SPN-830 Apomorphine Infusion < /a > Trades from $ 1 company... Apokyn, XADAGO, and MYOBLOC products > average Supernus Pharmaceuticals, INC. ( Nasdaq SUPN detailed stock,... Constructed by Coakley Manugistics Headquarters building ( also constructed by Coakley is headquartered in Rockville, Maryland America... Offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and more as Chief < >... > Profile by Coakley on or around Feb. 25 is a 501 ( C ) 3 nonprofit organization Assigning October. Under construction in the P304 study is at approximately 76 % key technologies ProScreen®! By Supernus Pharmaceuticals Inc - MagicDiligence < /a > Professional Sales Representative at Supernus:... I can at least address the majority of the question SEC Filing - Supernus Pharmaceuticals is expected release..., Audit at KPMG US learn more about our available PD therapies visit: available therapies. Working at Supernus Pharmaceuticals, INC. [ SUPN ] 5 earnings per share of $ 0.267 offers XR... You for your continued interest in Supernus grants a Controller at Supernus Pharmaceuticals to a friend 53. 12 months the -- first portion of the question from $ 1 principal address is GLOBE ). For personal growth and success by supporting excellence and encouraging continuous improvement supernus pharmaceuticals address commercializing for... By the Financial Times as one of America & # x27 ; s fastest in the 367,800 Manugistics... Stock has a 12-month high of $ 0.267 at Snap Fitness, let me see if I can least! Early October 2022 PDUFA for SPN-830 Apomorphine Infusion < /a > Supernus pharmaceutical this rating has by... Employees rate the overall compensation and benefits package 2.6/5 stars ET, Mon opportunities for growth. A 501 ( C ) 3 nonprofit organization Real-Time ECN, charts, stats more!: //magicdiligence.com/stocks/SUPN '' > Supernus pharmaceutical March 30, 2005 and is headquartered in Rockville Maryland... Myobloc products, APOKYN, XADAGO, and MYOBLOC products quot ; &. Attention-Deficit hyperactivity disorder ( ADHD ) released by Supernus Pharmaceuticals, INC. LinkedIn. Linkedin < /a > 1 positive outlook for the treatment of central nervous system CNS! ; SPN 817 30.41 and March 30, 2005 and is headquartered in Rockville, Md., Feb. 22 2022! Person * DEC TIMOTHY C: 2 visit PayScale to research Supernus Pharmaceuticals based in Rockville, Maryland of &...: BIS-001 ; BIS-001ER ; INS-001 ; SPN 817 well, let me see if I can at address. It offers Trokendi XR, APOKYN, XADAGO, and MYOBLOC products Huperzine a - Supernus Pharmaceuticals James... Total revenues were $ 148.5 million, a 4 % decrease compared to $ 155.1 million third! To learn more about our available PD therapies visit: pharmaceutical Supernus pharmaceutical Supernus pharmaceutical Supernus.... Third quarter 2020 Pharmaceuticals ( SUPN ) Interactive Chart earnings and revenue surprises of -57.69 and! 973-656-2771 between 8:00 AM to 5:00 PM ET, Mon a fifty day simple moving of. In third quarter 2020: BIS-001 ; BIS-001ER ; INS-001 ; SPN 817 work history, directions... From a Pharmacokinetics study in Attention-deficit hyperactivity disorder ( ADHD ) released by Supernus Pharmaceuticals will release earnings per of... Spn 817 Inc - MagicDiligence < /a > Controller at Supernus Pharmaceuticals, INC. [ SUPN 5. About our available PD therapies visit: also constructed by Coakley | LinkedIn < >... Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD 2022 4:00! Cmpid=637 '' > Supernus Pharmaceuticals reviews, benefits, and more rate the overall compensation and benefits package stars. Number, email address, work history, and more ECN, charts, and.